A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naive people

ResearchWorks/Manakin Repository

Search ResearchWorks


Advanced Search

Browse

My Account

Statistics

Related Information

A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naive people

Show simple item record

dc.contributor.author Schouten, Jeffrey T. en_US
dc.contributor.author Lockhart, David W. en_US
dc.contributor.author Rees, Thomas S. en_US
dc.contributor.author Collier, Ann C. en_US
dc.contributor.author Marra, Christina M. en_US
dc.date.accessioned 2010-05-06T20:04:50Z
dc.date.available 2010-05-06T20:04:50Z
dc.date.issued 2006 en_US
dc.identifier.citation chouten J, Lockhart D, Rees T, Collier A, Marra C. A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naive people. BMC Infectious Diseases. 2006;6(1):28. en_US
dc.identifier.other 10.1186/1471-2334-6-28 en_US
dc.identifier.uri http://www.biomedcentral.com/1471-2334/6/28 en_US
dc.identifier.uri http://hdl.handle.net/1773/15833
dc.description Professor. Authors Collier and Marra are also UW professors. Author Schouten is a UW physician. en_US
dc.description.abstract Background: While hearing loss in HIV-infected people after beginning nucleoside reverse transcriptase inhibitors (NRTIs) has been reported, there have been no prospective studies that measured hearing changes longitudinally in treatment-naive HIV-infected subjects following initiation of regimens containing NRTIs. The goal of this study was to conduct a prospective assessment of the contribution of zidovudine (ZDV) and didanosine (ddI) to hearing loss Methods/design: A prospective observational pilot study to determine whether ZDV or ddI, alone or in combination, are associated with sensorineural hearing loss in HIV-infected persons. Changes in hearing levels at all frequencies and in low and high frequency pure tone averages were measured at baseline, 16, and 32 weeks after initiating antiretroviral therapy. Discussion: Treatment with ZDV and ddI did not result in loss of hearing, even after taking into account noise exposure, immune status and age. The results of this prospective pilot study do not support the notion that treatment with nucleoside antiretrovirals damages hearing. en_US
dc.description.sponsorship UW Royalty Research Fund, and 1250 and UW CFAR (AI 27757). en_US
dc.language.iso en_US en_US
dc.title A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naive people en_US
dc.type Article en_US


Files in this item

Files Size Format View
1471-2334-6-28.pdf 233.3Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record